Amedeo Smart

Free Medical Literature Service

 

Amedeo

Antiretroviral Therapy
  Free Subscription

Articles published in
J Infect Dis
    August 2025
  1. LABARILE M, Schoepf IC, Pasin C, Oumelloul MA, et al
    Untargeted Metabolite Profile Associations with Body Mass Index, Waist-Hip Ratio, and Antiretroviral Therapy in >1300 People with HIV: the Swiss HIV Cohort Study.
    J Infect Dis. 2025 Aug 27:jiaf438. doi: 10.1093.
    >> Share

    July 2025
  2. MOHAN H, Nguyen J, Yee A, Laurette EY, et al
    Fetal Defects in Mice Treated with Integrase Strand Transfer Inhibitors: Comparison of Dolutegravir, Raltegravir, Bictegravir and Cabotegravir.
    J Infect Dis. 2025 Jul 15:jiaf362. doi: 10.1093.
    >> Share

    June 2025
  3. BAUERMEISTER JA, Arrington-Sanders R, Coleman-Lewis J, Bertagnolli LN, et al
    Safety, Pharmacokinetics, and Acceptability of a Tenofovir Rectal Microbicide Douche Among Young Men Who Have Sex with Men: The DREAM ATN Study (ATN 163).
    J Infect Dis. 2025 Jun 28:jiaf349. doi: 10.1093.
    >> Share

  4. PERAZZOLO S, Flexner CW, Stephen ZR, Acosta EP, et al
    Long-acting Injectable Containing Lopinavir Eliminates Reliance on Ritonavir Pharmacokinetic Enhancement.
    J Infect Dis. 2025 Jun 24:jiaf319. doi: 10.1093.
    >> Share

  5. DESCHENES NM, Perez-Vargas J, Zhong Z, Thomas M, et al
    Functional and structural characterization of treatment-emergent nirmatrelvir resistance mutations at low frequencies in the main protease (Mpro) reveals a unique evolutionary route for SARS-CoV-2 to gain resistance.
    J Infect Dis. 2025 Jun 3:jiaf294. doi: 10.1093.
    >> Share

    May 2025
  6. ZHENG R, Fuchs EJ, Nimmagadda S, Rohan LC, et al
    Anal Sex and Tenofovir Douche Sequence Impacts Colorectal Distribution of HIV Surrogate and Douche (DREAM-02).
    J Infect Dis. 2025 May 31:jiaf286. doi: 10.1093.
    >> Share

    April 2025
  7. MUNOZ-MUELA E, Mejias-Trueba M, Serna-Gallego A, Saborido-Alconchel A, et al
    Mitochondrial disorders after 12 months of HIV-1 preexposure prophylaxis based on tenofovir disoproxil fumarate plus emtricitabine in healthy adults.
    J Infect Dis. 2025 Apr 1:jiaf156. doi: 10.1093.
    >> Share

    February 2025
  8. YOUNAS M, Gimenez S, Lin YL, Mettling C, et al
    GABA-induced monocytic reactive oxygen species impair CD4 restoration in treated HIV-1 adults.
    J Infect Dis. 2025 Feb 4:jiaf058. doi: 10.1093.
    >> Share

    October 2024
  9. TOBIN NH, Brooker SL, Li F, Coombs RW, et al
    Use of an Ethinyl Estradiol/Etonogestrel Vaginal Ring Alters Vaginal Microbial Communities in Women with HIV.
    J Infect Dis. 2024 Oct 31:jiae524. doi: 10.1093.
    >> Share

  10. TERRAULT NA, Sterling R, Lok AS, Ghany MG, et al
    HBV RNA as a Biomarker for Safe Antiviral Discontinuation: A Prospective Study of Nucleos(t)ide Analogue Withdrawal.
    J Infect Dis. 2024 Oct 30:jiae541. doi: 10.1093.
    >> Share

  11. BAILON L, Puertas MC, Garcia-Guerrero MC, Moraes-Cardoso I, et al
    Impact of Dolutegravir plus Lamivudine as First-Line Antiretroviral Treatment on HIV-1 Reservoir and Inflammatory Markers in Peripheral Blood.
    J Infect Dis. 2024 Oct 28:jiae530. doi: 10.1093.
    >> Share

    September 2024
  12. SRINIVASAN S, Richardson BA, Wallis JM, Fiedler TL, et al
    Vaginal Bacteria and Proinflammatory Host Immune Mediators as Biomarkers of Human Immunodeficiency Virus Acquisition Risk Among African Women.
    J Infect Dis. 2024 Sep 9:jiae406. doi: 10.1093.
    >> Share

  13. DE SCHEERDER MA, Degroote S, Delporte M, Kiselinova M, et al
    In depth analysis of the HIV reservoir confirms effectiveness and safety of DTG/3TC in a phase 4 randomized controlled switch trial (RUMBA).
    J Infect Dis. 2024 Sep 3:jiae405. doi: 10.1093.
    >> Share

    July 2024
  14. LANTZ A, Kiweewa Matovu F, Johnson R, Isingel E, et al
    Female genital tract host factors and tenofovir and lamivudine active metabolites.
    J Infect Dis. 2024 Jul 24:jiae372. doi: 10.1093.
    >> Share

  15. KURITZKES DR
    Molnupiravir in Combination With Nirmatrelvir/Ritonavir: No Cause for Alarm.
    J Infect Dis. 2024 Jul 8:jiae214. doi: 10.1093.
    >> Share

  16. ZHOU S, Long N, Rosenke K, Jarvis MA, et al
    Combined Treatment of Severe Acute Respiratory Syndrome Coronavirus 2 Reduces Molnupiravir-Induced Mutagenicity and Prevents Selection for Nirmatrelvir/Ritonavir Resistance Mutations.
    J Infect Dis. 2024 Jul 8:jiae213. doi: 10.1093.
    >> Share

    June 2024
  17. WANG F, Rademeyer K, Namuju OC, Abdusalaamu K, et al
    Post-mortem analysis of dolutegravir, tenofovir, lamivudine and efavirenz penetration in multiple CNS compartments.
    J Infect Dis. 2024 Jun 20:jiae325. doi: 10.1093.
    >> Share

  18. JACOBSON DL, Crider KS, DeMarrais P, Brummel S, et al
    Dolutegravir- Versus Efavirenz-Based Treatment in Pregnancy: Impact on Red Blood Cell Folate Concentrations in Pregnant Women and Their Infants.
    J Infect Dis. 2024 Jun 15:jiae308. doi: 10.1093.
    >> Share

    May 2024
  19. MCCLUSKEY SM, Muyindike WR, Nanfuka V, Omoding D, et al
    Population Effectiveness of Dolutegravir Implementation in Uganda - A Prospective Observational Cohort Study (DISCO): 48-week Results.
    J Infect Dis. 2024 May 16:jiae260. doi: 10.1093.
    >> Share

  20. WU L, Kinuthia J, Anderson PL, Baeten JM, et al
    Drug concentrations in hair and dried blood spots as PrEP adherence metrics during pregnancy and postpartum.
    J Infect Dis. 2024 May 3:jiae208. doi: 10.1093.
    >> Share

    April 2024
  21. RIDDLER SA, Kelly CW, Hoesley CJ, Ho KS, et al
    A Phase 1 Clinical Trial to Assess the Safety and Pharmacokinetics of a Tenofovir Alafenamide/Elvitegravir Insert Administered Rectally for HIV Prevention.
    J Infect Dis. 2024 Apr 24:jiae211. doi: 10.1093.
    >> Share

  22. BEGRE L, Boyd A, Plissonnier ML, Testoni B, et al
    Circulating HBV RNA and hepatitis B core-related antigen trajectories in persons with HIV/HBV coinfection and HBsAg loss on tenofovir therapy.
    J Infect Dis. 2024 Apr 16:jiae189. doi: 10.1093.
    >> Share

    January 2024
  23. SCRIMIERI F, Bastian E, Smith M, Rehm CA, et al
    Transcriptionally-active "defective" HIV-1 proviruses and their association with immunological non-response to antiretroviral therapy.
    J Infect Dis. 2024 Jan 16:jiae009. doi: 10.1093.
    >> Share

    December 2023
  24. MAKAROVA N, Singletary T, Peet MM, Mitchell J, et al
    Extended post-exposure protection against vaginal SHIV infection with tenofovir alafenamide fumarate/elvitegravir inserts in macaques.
    J Infect Dis. 2023 Dec 22:jiad599. doi: 10.1093.
    >> Share

    November 2023
  25. WELD ED, McGowan I, Anton P, Fuchs EJ, et al
    Tenofovir Douche as HIV Pre-Exposure Prophylaxis for Receptive Anal Intercourse: Safety, Acceptability, Pharmacokinetics, & Pharmacodynamics (DREAM 01).
    J Infect Dis. 2023 Nov 29:jiad535. doi: 10.1093.
    >> Share

  26. ZIVICH PN, Cole SR, Edwards JK, Glidden DV, et al
    HIV prevention among men who have sex with men: tenofovir alafenamide combination preexposure prophylaxis versus placebo.
    J Infect Dis. 2023 Nov 16:jiad507. doi: 10.1093.
    >> Share

    September 2023
  27. BUTT AA, Yan P, Shaikh OS, Talisa VB, et al
    Nirmatrelvir/ritonavir Use and Hospitalizations or Death in Previously Uninfected Non-hospitalized High-risk Population with COVID-19: A matched cohort study.
    J Infect Dis. 2023 Sep 15:jiad393. doi: 10.1093.
    >> Share

    August 2023
  28. PARASKEVIS D, Gkova M, Mellou K, Gerolymatos G, et al
    Real-world effectiveness of molnupiravir and nirmatrelvir/ritonavir as treatments for COVID-19 in high-risk patients.
    J Infect Dis. 2023 Aug 11:jiad324. doi: 10.1093.
    >> Share

  29. SCEVOLA S, Niubo J, Domingo P, Verdejo G, et al
    Decay of human immunodeficiency virus (HIV) RNA in seminal plasma and rectal fluid in treatment-naive adults starting antiretroviral therapy with dolutegravir plus lamivudine or bictegravir/emtricitabine/tenofovir alafenamide.
    J Infect Dis. 2023 Aug 1:jiad304. doi: 10.1093.
    >> Share

    May 2023
  30. SCHWENKE JM, Thorball CW, Schoepf IC, Ryom L, et al
    Association of a Polygenic Risk Score with Osteoporosis in People Living with HIV: The Swiss HIV Cohort Study.
    J Infect Dis. 2023 May 24:jiad179. doi: 10.1093.
    >> Share

    December 2022
  31. DONNELLAN S, Pennington SH, Ruggiero A, Martinez-Rodriguez C, et al
    A quantitative method for the study of HIV-1 and Mycobacterium tuberculosis co-infection.
    J Infect Dis. 2022 Dec 20:jiac491. doi: 10.1093.
    >> Share

    October 2022
  32. JAO J, Sun S, Bonner LB, Legbedze J, et al
    Lower insulin sensitivity in newborns with in utero HIV and antiretroviral exposure who are uninfected in Botswana.
    J Infect Dis. 2022 Oct 14. pii: 6761332. doi: 10.1093.
    >> Share

  33. ESHLEMAN SH, Fogel JM, Halvas EK, Piwowar-Manning E, et al
    HIV RNA screening reduces integrase strand transfer inhibitor resistance risk in persons receiving long-acting cabotegravir for HIV prevention.
    J Infect Dis. 2022 Oct 14. pii: 6761331. doi: 10.1093.
    >> Share

    September 2022
  34. SMITH MSR, Mohan H, Ajaykumar A, Hsieh AYY, et al
    Second-generation HIV integrase inhibitors induce differentiation dysregulation and exert toxic effects in human embryonic stem cell and mouse models.
    J Infect Dis. 2022 Sep 19. pii: 6704757. doi: 10.1093.
    >> Share

  35. AVERY RK, Prono MVD
    Bebtelovimab in the Real World: Promise and Fulfillment.
    J Infect Dis. 2022 Sep 17. pii: 6702587. doi: 10.1093.
    >> Share

  36. RAZONABLE RR, O'Horo JC, Hanson SN, Arndt RF, et al
    Outcomes of Bebtelovimab Treatment is Comparable to Ritonavir-boosted Nirmatrelvir among High-Risk Patients with Coronavirus Disease-2019 during SARS-CoV-2 BA.2 Omicron Epoch.
    J Infect Dis. 2022 Sep 17. pii: 6702534. doi: 10.1093.
    >> Share

  37. HALL SA, Burns GS, Mooney BJ, Millen R, et al
    Hepatitis B Virus Flares following Nucleot(s)ide Analogue Cessation Are Associated with Activation of TLR Signalling Pathways.
    J Infect Dis. 2022 Sep 15. pii: 6701634. doi: 10.1093.
    >> Share

    March 2022
  38. ESHLEMAN SH, Fogel JM, Piwowar-Manning E, Chau G, et al
    Characterization of Human Immunodeficiency Virus (HIV) Infections in Women Who Received Injectable Cabotegravir or Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Prevention: HPTN 084.
    J Infect Dis. 2022 Mar 18. pii: 6549543. doi: 10.1093.
    >> Share

    August 2021
  39. PALICH R, Teyssou E, Sayon S, Abdi B, et al
    Kinetics of archived M184V mutation in treatment-experienced virally suppressed HIV-infected patients.
    J Infect Dis. 2021 Aug 20. pii: 6355381. doi: 10.1093.
    >> Share

    March 2021
  40. LOHMAN-PAYNE B, Koster J, Gabriel B, Chilengi R, et al
    Persistent Immune activation in HIV-Infected Pregnant Women Initiating cART Post Conception.
    J Infect Dis. 2021 Mar 29. pii: 6199840. doi: 10.1093.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016